BJMO - 2021, issue Special, december 2021
J. Blokken PhD, PharmD, T. Feys MBA, MSc
SABCS 2020 featured several interesting presentations in the field of radiotherapy. The PRIME 2 study investigated the impact of omitting postoperative whole breast radiotherapy in older, low-risk women with early invasive breast cancer. Outcomes of the phase III BIG 3-07/TROG 07.01 trial were also reported providing improved insights into the optimal radiation dose and fractionation schedule for non-low risk ductal carcinoma in situ of the breast. Other interesting topics included the comparison of patient and physician reports of toxicity after breast radiotherapy and the finding that radiation therapy improves survival in early-stage HER2-positive breast cancer with a high-levels of tumour infiltrating lymphocytes. Finally, we report on the results of a retrospective analysis assessing the feasibility of radiation therapy de-escalation in patients with stage I, node-negative, HER2-positive breast cancer.
Read moreBJMO - 2021, issue Special, december 2021
A. Dekker MD, T. Feys MBA, MSc
We want you to be completely up to date on the results presented at SABCS 2020, hence this article will focus on three presentations that were not previously addressed in the congress highlights. A first presentation reported on the high rate of persistent controlled substance use following mastectomy with reconstruction surgery. Results of a large systematic review and meta-analysis provide solid evidence on the chance of pregnancy after breast cancer and underscores the importance of oncofertility counselling. A third interesting study performed a large, pooled analysis to further define and explore the role of circulating tumor cell count as a tool for early treatment monitoring in patients with metastatic breast cancer (MBC).
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
